[ Back to EurekAlert! ]

Contact: Garth Sundem
University of Colorado Denver

Tracey Schefter, University of Colorado Cancer Center

Caption: University of Colorado Cancer Center investigator Tracey Schefter, M.D., and colleagues report promising results for the addition of bevacizumab (Avastin) to standard of care in locally advanced cervical cancer.

Credit: UC Denver

Usage Restrictions: None

Related news release: Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'

[ Back to EurekAlert! ]